Editor's note: Every morning, James Altucher presents the most timely, topical posts from the Web's best business blogs. As always, let us know what you think.

More than 50% down from its IPO price, can Vonage ( VG) finally be worth looking at?

Crossing Wall Street addresses the question that all the permabears keep alluding to: Is the U.S. bankrupt?

Once and for all, CXO Advisory takes a look at the end-of-the-month effect.

InvestorGeeks figures out how to find the boring guys that benefit from the hot sectors. The blog post narrows in on FedEx ( FDX).

Blogging Stocks looks at the Tel Aviv exchange amidst all of the conflict there.

Henry Blodget gushes about Google ( GOOG) but then tears it down.

I want to be in stealth mode also.

Wow, this might be sour grapes. But a Yahoo! engineer writing on Seeking Alpha trashes Google's earnings report and calls the search slowdown industrywide.

Speaking of search, this analysis by Read/WriteWeb of the different generations of search technology is interesting, although I'm not sure I buy into what he's saying with "search 3.0." User-generated content is all fine and good until it becomes too much work, then I'm right back to Google.

I am not a believer in buying momentum stocks, but I was really surprised to see on GotFrank's list of new 52-week highs that Oracle ( ORCL) was making an appearance. How strange for Microsoft ( MSFT) to be near 52-week lows and Oracle near 52-week highs.

When a stock is called Animal Cloning Sciences ( ANML) and has lines like this in their 10K: "The Company expects that its research in cloning and freezing horse embryos will have an application in freezing cat and dog embryos," you know that Pink Sheets isn't far behind.

Ten Ways To Drive Traffic To Your Web Site. And speaking of building an Internet business, Guy Kawasaki reviews Chris Anderson's book The Long Tail.

Post of the day: Top 10 Dumbest Online Business Ideas that Made It Big Time.

I used to have a pool table, but I couldn't do any of this.

Please note that due to factors including low market capitalization and/or insufficient public float, we consider Animal Cloning Sciences to be a small-cap stock. You should be aware that such stocks are subject to more risk than stocks of larger companies, including greater volatility, lower liquidity and less publicly available information, and that postings such as this one can have an effect on their stock prices.

At the time of publication, Altucher and/or his fund had no positions in stocks mentioned, although positions may change at any time.

James Altucher is a managing partner at Formula Capital, an alternative asset management firm that runs several quantitative-based hedge funds as well as a fund of hedge funds. He is also the author of Trade Like a Hedge Fund and Trade Like Warren Buffett. Under no circumstances does the information in this column represent a recommendation to buy or sell stocks. Altucher appreciates your feedback; click here to send him an email.

Interested in more writings from James Altucher? Check out his newsletter, TheStreet.com Internet Review. For more information, click here.

TheStreet.com has a revenue-sharing relationship with Trader's Library under which it receives a portion of the revenue from purchases by customers directed there from TheStreet.com.